Advancements in Pulsed Field Ablation: The VARIPULSE Pro Platform Launch
Johnson & Johnson’s launchs the VARIPULSE Pro Platform in Europe. Pulsed field ablation has advanced significantly with the introduction of a new pulse sequence that delivers ablation lesions five times faster than the previous version while maintaining equivalent lesion quality and the established safety profile.
The platform builds on the original VARIPULSE pulsed field ablation system, now approved with CE Mark, and integrates seamlessly with the CARTO 3 mapping system. This combination supports precise lesion delivery and consistent catheter positioning when used with intracardiac echocardiography.
Faster, Cooler, Smarter Pulse Sequence
The core innovation in VARIPULSE Pro is a revised pulse sequence with a lower temperature profile than both the original VARIPULSE sequence and competing pulsed field ablation devices. Preclinical testing confirms it creates equivalent lesions in a fraction of the time, directly improving procedural workflow without compromising precision or safety. Early user feedback from the ongoing VARIPURE study highlights smoother operation and maintained accuracy in lesion sets.
Real-World Evidence Drives European Launch
The introduction of this next-generation platform is supported by robust preclinical data and real-world evidence from the inspIRE trial and other registries. These studies previously demonstrated strong safety outcomes and one-year effectiveness in paroxysmal atrial fibrillation ablation. The VARIPURE multicenter post-market study continues this evidence generation, with twelve-month interim results scheduled for presentation at the European Heart Rhythm Association (EHRA) PFA Summit.
Efficiency Gains with Economic Impact
By dramatically shortening ablation delivery time, VARIPULSE Pro has the potential to reduce overall procedure duration, lower staffing and anesthesia needs, and increase catheter lab throughput. These gains are particularly relevant in European markets where procedural efficiency directly influences cost-effectiveness and hospital resource utilization. As pulsed field ablation matures, health economic analyses will play a key role in quantifying its long-term value in atrial fibrillation management.
